MAPT

Microtubule-associated protein tau · P10636 · MAPT on Sugi Atlas →

6,631,907 patent compounds predicted against MAPT, 3,184,502 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1862	0.62	10/20
SCHEMBL1863	0.62	10/20
Tretinoin (SCHEMBL3145)	1.00	9/20
Tretinoin (SCHEMBL3146)	1.00	9/20
Tretinoin (SCHEMBL3952)	1.00	9/20
Cefazolin (SCHEMBL2841)	0.86	9/20
Cefazolin (SCHEMBL2842)	0.86	9/20
Ergotamine (SCHEMBL1483)	0.84	9/20
Cephalothin (SCHEMBL2990)	1.00	8/20
Vinblastine (SCHEMBL3549)	1.00	8/20
Vinblastine (SCHEMBL3550)	1.00	8/20
Vinblastine (SCHEMBL3628)	1.00	8/20
Vinblastine (SCHEMBL3629)	1.00	8/20
Vincristine (SCHEMBL3710)	1.00	8/20
Cephaloridine (SCHEMBL3936)	1.00	8/20
Vincristine (SCHEMBL3998)	1.00	8/20
Vincristine (SCHEMBL3709)	0.97	8/20
Vincristine (SCHEMBL3999)	0.97	8/20
Cephapirin (SCHEMBL3205)	0.84	8/20
Phenazopyridine (SCHEMBL270)	0.77	8/20

Clinical trials — most relevant to MAPT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)	PHASE4	COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age	PHASE2	ACTIVE_NOT_RECRUITING
A Multicenter Study of NAP (AL-108) in Schizophrenia	PHASE2	COMPLETED
Memantine Therapy in Amyotrophic Lateral Sclerosis	PHASE2	COMPLETED
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations	PHASE2	COMPLETED
A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI	PHASE2	ENROLLING_BY_INVITATION
Pharmacological Enhancement of Glymphatic Function in Humans	PHASE1/PHASE2	COMPLETED
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease	PHASE1	COMPLETED
Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults	PHASE1	COMPLETED
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease	PHASE1	COMPLETED
Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia	PHASE1	UNKNOWN
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology	PHASE1	RECRUITING
Evaluation of a Novel PET Radioligand to Image OGA	nan	COMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING
Human CNS Tau Kinetics in Tauopathies	nan	COMPLETED
Comparison of OCTA Factors in Patients With or Without Amyloid Pathology: A Prospective Study	nan	COMPLETED
Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous System	nan	ENROLLING_BY_INVITATION
Neurofilament Surveillance Project (NSP)	nan	ACTIVE_NOT_RECRUITING
tACS for Amyloid-β Reduction in Alzheimer's Disease	nan	COMPLETED
Retinal Metabolic Imaging of Alzheimer Patient	nan	COMPLETED
Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy	nan	COMPLETED
A Pilot Study of Deep Cervical Lymphatic-venous Anastomosis in the Treatment of Alzheimer's Disease	nan	NOT_YET_RECRUITING
Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers	nan	COMPLETED
F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)	nan	ENROLLING_BY_INVITATION
Imaging Tau Deposition in the Brain of Elderly Subjects	nan	ACTIVE_NOT_RECRUITING
Estimate of the TSD Based on the Quantification of the Tau Protein in CSF	nan	UNKNOWN
Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients	nan	COMPLETED
CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease	nan	COMPLETED
Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAPT binder may also engage these)

Protein	Name	Similarity
Q5S6V2	—	1.000	Q5S6V2 →
Q5YCW0	—	1.000	Q5YCW0 →
Q5YCW1	—	1.000	Q5YCW1 →
Q5YCV9	—	1.000	Q5YCV9 →
P19332	—	1.000	P19332 →
P10637	—	1.000	P10637 →
O88737	—	0.996	O88737 →
A6X8Z5	—	0.995	A6X8Z5 →
O54963	—	0.995	O54963 →
TET3	Methylcytosine dioxygenase TET3	0.995	landscape →
P29172	—	0.995	P29172 →
A4IFJ0	—	0.994	A4IFJ0 →
D6RIA3	—	0.994	D6RIA3 →
P58871	—	0.993	P58871 →
Q9JIX8	—	0.993	Q9JIX8 →
P0C671	—	0.993	P0C671 →
Q9JL04	—	0.993	Q9JL04 →
Q8K0T0	—	0.993	Q8K0T0 →
A1L170	—	0.993	A1L170 →
Q8VIG1	—	0.993	Q8VIG1 →
Q5VV67	—	0.993	Q5VV67 →
Q95208	—	0.993	Q95208 →
CBX4	E3 SUMO-protein ligase CBX4	0.992	landscape →
Q8C5W0	—	0.992	Q8C5W0 →
Q80U49	—	0.992	Q80U49 →
P49342	—	0.992	P49342 →
O88778	—	0.992	O88778 →
Q8BZ32	—	0.992	Q8BZ32 →
Q6NZN1	—	0.992	Q6NZN1 →
KDM3B	Lysine-specific demethylase 3B	0.992	landscape →